Cellectis’ allogeneic portfolio gets boost

France-based Cellectis SA has acquired a new partner for its portfolio of products for cancer that are based on donor T cells that have been engineered to target specific antigen on cancer cells. The allogeneic portfolio had been licensed to Pfizer Inc and Servier.

Full text available to subscribers only. Click here for information on subscribing to MedNous.